Abstract
Hitherto no therapeutic has received regulatory approval for the treatment of post-COVID-19 condition (PCC). Cognitive deficits, mood symptoms and significant reduction in health-related quality of life (HRQoL) are highly replicated and debilitating aspects of PCC. We sought to...
https://www.cambridge.org/core/journals/international-psychogeriatrics/article/p149-chronic-fatigue-syndrome-and-its-response-to-the-use-of-a-multimodal-antidepressant/E13A225834DBB9896ED2114B1A4A1A86
P149: Chronic fatigue syndrome and its response to the use of a multimodal antidepressant...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.